Prof. Andrew Scott leads the Tumour Targeting Program at the Olivia Newton-John Cancer Research Institute and co-Director, Centre for Research Excellence in Brain Tumours; is Director, Department of Molecular Imaging and Therapy, Austin Health; and is Professor, La Trobe University University of and Melbourne. His clinical and research interests are focused on developing innovative strategies for targeted therapy of cancer (particularly with monoclonal antibodies), molecular imaging in oncology, and global advocacy in Oncology and Nuclear Medicine. His laboratory has been involved in the preclinical development and first-in-man trials of numerous recombinant antibodies in cancer patients, and seven antibodies developed in his laboratory have been licenced to Biotech and Pharma companies, and have entered Phase I/II/III trials. He has published 398 peer reviewed papers and 27 book chapters, is an inventor on 22 patents, and is a founder of a biotech company. Prof. Scott is a member of the Strategic Advisory Committee for the National Imaging Facility, a member of the Scientific Committee of ARTnet, and Federal Council member of the Australian and New Zealand Society of Nuclear Medicine. In 2017 he was awarded Member (AM) in the General Division of the Order of Australia, and elected a Fellow of the Australian Academy of Health and Medical Sciences.
